Jump to: Page Content, Site Navigation, Site Search,
You are seeing this message because your web browser does not support basic web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.
BMJ 2004;329:172 (17 July), doi:10.1136/bmj.329.7458.172
| The first 150 words of the full text of this article appear below. |
EDITORIn their randomised controlled trial of gingko biloba and acetazolamide for preventing acute mountain sickness Gertsch et al do not include data on eligible trekkers who declined enrolment.1 These data are important as the trial participants may not be representative of all non-Nepali trekkers. A bias in participants may underestimate the effectiveness of either agent. This is particularly important for gingko, which is stated to be no more effective than placebo.
|
|
Credit: ERNST HAAS/GETTY
|
Many trekkers arriving in Nepal will have established views on drug treatments for altitude sickness. Some will already be in possession of their drug of choice. Such people are likely to refuse randomisation to drug or placebo and will therefore have been excluded from the trial. If a significant number of these had perceived prior benefit from gingko, its effectiveness will have been underestimated.
From the information provided it is impossible to comment on
Heather L Elphick, specialist registrar, geriatric medicine
Northern General Hospital, Sheffield S5 7AU elphickdh@hotmail.com
David A Elphick, specialist registrar, gastroenterology
Royal Hallamshire Hospital, Sheffield S10 2JF